Wikipedia -WSS

Wikipedia

author：focus 2025-09-27 12:55:58 - browse：59

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

WSS

NIH documents show early flaws of $1.6 billion long Covid program

Parkinson’s finding may lead to tests and, someday, treatments

NIH documents show early flaws of $1.6 billion long Covid program

Copay coupons to count toward deductibles, after Biden court move

BMI, flaws aside, is found to be useful estimate of body fat in youth

Biotech venture capitalists face new demands from investors

hotspot

Wikipedia

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

United colonoscopy coverage change 'may cost lives,' doctors say

Parkinson’s finding may lead to tests and, someday, treatments

After affirmative action ruling, medical educators look to 'holistic review'

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

At least 13 dead in Texas as scorching temps continue

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Medical records are filled with copy

Why doctors need education on FDA device approval process

focus

Let's speed up science by embracing open access publishing

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

The Pandemic Treaty must support building strong health systems

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Let's speed up science by embracing open access publishing

Biotech venture capitalists face new demands from investors

knowledge

focus

knowledge

focus